Coronary Heart Disease News and Research

RSS

Genzyme and Isis Pharmaceuticals announce phase 3 study data of mipomersen

Genzyme Corp. and Isis Pharmaceuticals Inc. announced that data from the phase 3 study of mipomersen in patients with homozygous familial hypercholesterolemia (hoFH) were presented today at the American Heart Association’s Scientific Sessions.

17 Nov 2009

Consortium to define new modalities for treating hypertension and associated vascular complications

Top Institute Pharma has formed a consortium with Actelion Pharmaceuticals Ltd, Erasmus Medical Centre and Maastricht University to define new modalities for the treatment of hypertension (high blood pressure) and associated vascular complications such as heart and kidney failure, myocardial infarction and stroke.

17 Nov 2009

Aterovax presents results of its sPLA2 activity test in the PEACE trial

Aterovax SA, a company developing innovative products for atherosclerosis, today announced data demonstrating that its blood test for secretory phospholipase A2 (sPLA2) activity significantly improves cardiovascular risk prediction in patients with stable coronary artery disease (CAD) over a 5 year period, independent of established risk markers, including C-reactive protein.

17 Nov 2009

Erratic heart rhythms during exercise do not pose risk to healthy, older adults

Healthy, older adults free of heart disease need not fear that bouts of rapid, irregular heartbeats brought on by vigorous exercise might increase short- or long-term risk of dying or having a heart attack, according to a report by heart experts at Johns Hopkins and the U.S. National Institute on Aging (NIA).

17 Nov 2009

Statin therapy should still be used first to reach blood cholesterol levels before considering niacin

Heart experts at Johns Hopkins are calling premature the early halt of a study by researchers at Walter Reed Army Medical Center and Washington Hospital Center on the benefits of combining extended-release niacin, a B vitamin, with cholesterol-lowering statin medications to prevent blood vessel narrowing. Cardiovascular atherosclerosis, as it is also known, is believed responsible for one in three deaths in the United States each year.

17 Nov 2009

China Medicine reports total revenues of $19.2M for the third quarter of 2009

China Medicine Corporation, a developer and a leading distributor of prescription and over-the-counter pharmaceuticals, traditional Chinese medicines (TCM), nutritional and dietary supplements, and medical devices and medical formulations, today announced its third quarter 2009 results.

16 Nov 2009

FDA issues a Complete Response Letter for Human Genome Sciences' raxibacumab BLA

Human Genome Sciences, Inc. today announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) relating to the Company’s Biologics License Application (BLA) requesting the approval of raxibacumab for use in the treatment of inhalational anthrax. The FDA issues Complete Response Letters to request additional information needed to complete the review of a BLA.

16 Nov 2009

Transcendental Meditation lowers rates of heart attack, stroke, and death

Patients with coronary heart disease who practiced the stress-reducing Transcendental Meditation® technique had nearly 50 percent lower rates of heart attack, stroke, and death compared to nonmeditating controls, according to the results of a first-ever study presented during the annual meeting of the American Heart Association in Orlando, Fla., on Nov.16, 2009.

16 Nov 2009

Results from first-in-man study of NO-donating HMG-CoA Reductase Inhibitor released

NicOx S.A. today announced that a phase 1b, first-in-man study for NCX 6560, versus placebo and Lipitor® (atorvastatin), has met its primary and secondary objectives. The top-line results demonstrated very good safety and tolerability for all the tested doses of NCX 6560, as well as the expected cholesterol lowering profile.

13 Nov 2009

Artificially increasing selenium status above the level required is unwarranted, study calls for further research

A new study from the University of Warwick has discovered taking too much of the essential mineral selenium in your diet can increase your cholesterol by almost 10%.

12 Nov 2009

Lipid assessment in vascular disease can be simplified by measuring cholesterol levels

Lipid assessment in vascular disease can be simplified by measuring either total and HDL cholesterol levels or apolipoproteins, without the need to fast and without regard to triglyceride levels, according to a study in the November 11 issue of JAMA.

11 Nov 2009

NIH grants $1 million to study whether Transcendental Meditation can prevent future heart attacks in CHD patients

The National Institutes of Health's National Heart, Lung, and Blood Institute will fund a $1 million collaborative study by the Center for Natural Medicine and Prevention at Maharishi University of Management Research Institute and Columbia University Medical Center to determine whether the stress-reducing Transcendental Meditation technique can help patients with coronary heart disease (CHD) prevent future heart attacks, strokes and death.

7 Nov 2009

CABG completed "off-pump" has no advantages in patient outcomes: Study

A study of 2,203 cardiac surgery patients from Veterans Affairs (VA) medical centers nationwide revealed that coronary-artery bypass grafting (CABG) completed "off-pump," meaning without a heart-lung machine, had no advantages in patient outcomes compared to the traditional "on-pump" procedure.

6 Nov 2009

Declining kidney function linked to higher risk of heart failure in individuals with or without kidney disease

Declining kidney function is linked to a higher risk of heart failure, heart attack, peripheral arterial disease, and early death in individuals with or without kidney disease, according to a pair of studies appearing in an upcoming issue of the Journal of the American Society Nephrology (JASN).

6 Nov 2009

Scientists develop technique to predict new target diseases for existing drugs

Scientists at the University of North Carolina at Chapel Hill School of Medicine and the University of California, San Francisco have developed and experimentally tested a technique to predict new target diseases for existing drugs.

4 Nov 2009

Higher testosterone levels in older women are associated with increased health risks

Postmenopausal women who have higher testosterone levels may be at greater risk of heart disease, insulin resistance and the metabolic syndrome compared to women with lower testosterone levels, according to a new study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM).

4 Nov 2009

Dietary cholesterol is not a primary factor for coronary heart disease

Contrary to the established view, current data suggest that dietary cholesterol is not a primary factor of or causes heart disease - with the possible exception of the genetic forms of familial hypercholesterolemias. For instance, recent clinical trials evaluating the effect of cholesterol-lowering drugs on the development of chronic heart failure, diabetes and stroke have yielded disappointing results.

2 Nov 2009

BENLYSTA meets primary endpoint in BLISS-76 trial for systemic lupus erythematosus

Human Genome Sciences, Inc. and GlaxoSmithKline PLC (GSK) today announced that BENLYSTA™ (belimumab) met the primary endpoint in BLISS-76, the second of two pivotal Phase 3 trials in seropositive patients with systemic lupus erythematosus (SLE). BLISS-76 study results through 52 weeks showed that belimumab 10 mg/kg plus standard of care achieved a statistically significant improvement in patient response rate as measured by the SLE Responder Index at Week 52, compared with placebo plus standard of care.

2 Nov 2009

Recent releases in Global Health

"Action always leads to reaction, a fundamental law of nature," write the authors of an introduction appearing in a Journal of Acquired Immune Deficiency Syndromes (JAIDS) supplemental issue that focuses on global health systems.

30 Oct 2009

CCS updates the Canadian guidelines for the management and treatment of dyslipidemia

The management of dyslipidemia continues to evolve and despite improvements in recurrent cardiovascular events and a decrease in cardiac mortality, cardiovascular disease (CVD) still represents the major burden of disease in this country.

29 Oct 2009

Coronary Heart Disease News and Research

Genzyme and Isis Pharmaceuticals announce phase 3 study data of mipomersen

Consortium to define new modalities for treating hypertension and associated vascular complications

Aterovax presents results of its sPLA2 activity test in the PEACE trial

Erratic heart rhythms during exercise do not pose risk to healthy, older adults

Statin therapy should still be used first to reach blood cholesterol levels before considering niacin

China Medicine reports total revenues of $19.2M for the third quarter of 2009

FDA issues a Complete Response Letter for Human Genome Sciences' raxibacumab BLA

Transcendental Meditation lowers rates of heart attack, stroke, and death

Results from first-in-man study of NO-donating HMG-CoA Reductase Inhibitor released

Artificially increasing selenium status above the level required is unwarranted, study calls for further research

Lipid assessment in vascular disease can be simplified by measuring cholesterol levels

NIH grants $1 million to study whether Transcendental Meditation can prevent future heart attacks in CHD patients

CABG completed "off-pump" has no advantages in patient outcomes: Study

Declining kidney function linked to higher risk of heart failure in individuals with or without kidney disease

Scientists develop technique to predict new target diseases for existing drugs

Higher testosterone levels in older women are associated with increased health risks

Dietary cholesterol is not a primary factor for coronary heart disease

BENLYSTA meets primary endpoint in BLISS-76 trial for systemic lupus erythematosus

Recent releases in Global Health

CCS updates the Canadian guidelines for the management and treatment of dyslipidemia

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News